GLP-1 Daily: Ozempic & Wegovy News
FDA Warns RonanRx Over 'FDA-Approved Compounded' GLP-1 Claims; New Zealand's Pharmac Still Isn't Funding Wegovy; Doctors Push Back on an Off-Label Estimate
Wednesday, November 4, 2026 · 8 min
The FDA sent a warning letter to RonanRx over how it marketed compounded semaglutide and tirzepatide, and New Zealand's Pharmac says Wegovy for weight loss remains unfunded despite a high-priority recommendation. Plus, obesity doctors respond to a study estimating more than a million Americans may take GLP-1s off-label.
Listen
Show notes
The FDA sent a warning letter to RonanRx over how it marketed compounded semaglutide and tirzepatide, and New Zealand's Pharmac says Wegovy for weight loss remains unfunded despite a high-priority recommendation. Plus, obesity doctors respond to a study estimating more than a million Americans may take GLP-1s off-label.
In this episode
- RonanRx, Inc. dba RonanRx - 737905 - 10/30/2026 — U.S. Food and Drug Administration
“The following claims concerning compounded semaglutide and tirzepatide products appear on your website: “Well-Studied Compounded Medications,” accompanied by the description, “Compounded medications with substantial human clinical evidence—randomized trials, mechanistic studies,…”
- Wegovy and Mounjaro for weight loss not funded - Pharmac | Te Pātaka Whaioranga | NZ Government — Pharmac, Te Pātaka Whaioranga, NZ Government
“The Obesity Treatment Advisory Group recommended that Pharmac fund semaglutide (Wegovy) for chronic weight management in people with a high Body Mass Index (BMI) and associated comorbidities with a high priority.”
- A Million People in US May Take GLP-1s Off-Label — Virginia Anderson
“The issue is complicated because GLP-1s are available online without a prescription — and without the benefit of medical oversight while taking them. And PCPs are increasingly being asked about the drugs, originally approved to treat diabetes and later, obesity and overweight…”